Oxytocin is a small peptide hormone with multiple sites of action in human body. It regulates a large number of reproduction-related processes in all species. Particularly important is its ability to stimulate uterine contractility. This is achieved by multiple mechanisms involving sarcoplasmic reticulum Ca 2+ release and sensitization of the contractile apparatus to Ca
Oxytocin receptor system and human reproduction
Human parturition is a complex sequence of events that concludes in the coordinated processes of cervical dilation and uterine contraction. For most of human pregnancy the myometrium remains relatively quiescent, allowing development of the fetus. Towards the end of pregnancy, there is a relatively gradual change from myometrial quiescence to a more contractile state. The transformation of the uterine muscle from quiescent to contractile was termed "activation" and is thought to involve increased synthesis of contraction-associated proteins [1, 2] . Activation prepares the uterus for labor and alters it from a relatively insensitive organ to a sensitive, pro-contractile organ. Once the uterus has become activated, a process termed "stimulation" initiates the powerful coordinated contractions of labor. It is accepted that nonapeptide hormone oxytocin has a fundamental role in the stimulation process, and there is growing evidence that this hormone might also contribute to the process of activation as well.
Oxytocin was first extracted from the human posterior pituitary in1906 by Sir Henry Dale [3] . The chemical structure of oxytocin was determined in 1953 by Du Vigneaud et al [4] . Soon after the discovery of its uterotonic activity, the pituitary extract was used for treatment of postpartum hemorrhage [5] . Half a century later, obstetricians started using oxytocin for induction of labor [6] . In recent years, it has become apparent that oxytocin is involved in a much greater number of reproduction-related processes. Apart from modulating the uterine contractions during parturition, oxytocin is essential for milk ejection during lactation [7] . Furthermore, the widespread distribution of oxytocin receptors in the brain and the specific behavioral effects of centrally applied oxytocin point towards its role as a central neurotransmitter mediating reproduction-related processes such as maternal behavior, sexual receptivity and partnership bonding [8] . For in-depth discussion on different aspects of oxytocin biology the reader is referred to several detailed reviews published in the last few years [9] [10] [11] [12] [13] . In the present paper, we will reflect on our own work and the work of other groups on oxytocin-induced modulation of uterine contractility. Because oxytocin is one of the most potent uterotonic agents known, its effect on uterine contractility is of major pharmacological importance. Thus, synthetic analogs of oxytocin are widely used to induce labor and to treat postpartum hemorrhage. Premature activation of the oxytocin system might be a leading cause of preterm labor, therefore the antagonists of oxytocin receptors have been extensively tested as means of inhibiting premature uterine contraction. The effectiveness of atosiban, one of the most potent oxytocin receptor antagonists, has been tested in clinical trials [14, 15] . Based on these studies, atosiban is currently approved for clinical use in 29 countries. Despite the extensive clinical use of oxytocin and oxytocin receptor inhibitors, the molecular and cellular mechanisms underlying oxytocin-induced modulation of uterine contractility are not completely understood. The oxytocin receptor belongs to the G-protein coupled receptor family. After binding oxytocin, the receptor activates phospholipase-Cβ by coupling to G q /G 11 GTPbinding proteins [16] . This leads to the generation of the 2 second messengers: inositol 1,4,5-trisphosphate (IP 3 ); and diacylglycerol (DAG). Both second messengers are believed to be involved in the generation of the physiological response to oxytocin [17, 18] , although their relative contributions to the overall effect are unknown. There is substantial evidence in published reports that cytoplasmic Ca 2+ concentration ([Ca 2+ ] i ) determines myometrial contraction and is involved in stimulatory action of oxytocin [19] . However important, the IP 3 -mediated [Ca 2+ ] i release does not appear to be the whole story. Disabling the sarcoendoplasmic reticulum (SR) using a specific SR Ca 2+ ATP-ase inhibitor, thapsigargin, does not abolish the oxytocin-induced increase in the amplitude of myometrial contractions ( Figure 1 ). An example of changes in spontaneous contractions of an isolated strip of human myometrium in response to oxytocin application is given in Figure 1A . At least three distinct components can be discerned in the effect of oxytocin on human uterine smooth muscle: (1) increase in frequency of contractions; (2) initial transient increase in the base tone (incomplete relaxation); and (3) long-lasting increase in the amplitude and duration of phasic contractions. Even prolonged treatment (more than 1 h) of the myometrium with thapsigargin to disable the SR abolishes only the first 2 components of the oxytocin effect and does not change the third. That is, the oxytocin-induced increase in frequency of contractions and the transient rise in base tone are eliminated, but not the oxytocin-induced potentiation of force ( Figure 1B ). These data indicate that, in addition to the IP 3 -mediated Ca 2+ release, other processes might be involved in oxytocin-induced modulation of myometrial contractility. We will discuss these after reviewing the oxytocin-induced [Ca 2+ ] i signaling.
Oxytocin-mediated Ca

2+ release and excitationcontraction coupling in myometrium
Myometrium is a phasic smooth muscle with an intrinsic ability to generate spontaneous contractions. It is generally accepted that myometrial contractions are myogenic, that is, neural or hormonal stimuli are not required for the contractions to occur, but do modulate them. Slow depolarization of the myometrium preceding the discharge of action potentials is attributed to the activity of certain cells, considered pacemaker cells. In some types of visceral smooth muscle, for example, gastrointestinal [20] , urogenital [21] and vascular [22] , a specialized type of cell called interstitial cells of Cajal (ICC) had been found. In some, but not all tissues, these cells constitute a pacemaking mechanism. Our recent study has identified the ICC-like cells in human and rat myometrium [23] . It is therefore a plausible scenario that the multiple components in the effect of oxytocin are due to its action on different cell types within the myometrium. The ICC-like cells might mediate changes in frequency, whereas smooth muscle cells are responsible for the increase in amplitude of contractions. More research into this area is needed to make informed conclusions regarding the role of ICC-like cells in the regulation of myometrial contractility.
Several research groups have investigated oxytocin-induced [Ca 2+ ] i signaling using Ca 2+ sensitive dyes in primary cultures of rat [24] , human myometrial cells [25] and in a cell line derived from pregnant human myometrium [26, 27] . In all types of cells studied, these transients persisted in Ca 2+ -free solu- [25] . These data might suggest that oxytocin completely emptied the store during the first application and there was nothing left for the subsequent applications. Alternatively, the ineffectiveness of multiple applications of oxytocin might reflect a steep dependence of the IP 3 ] L will render the IP 3 receptors insensitive to IP 3 [28] . The extent to which a single application of oxytocin depletes the SR is important because store depletion can trigger capacitative Ca 2+ entry through store-operated Ca 2+ channels on the surface membrane. Several isoforms of TrpC have been identified in the myometrium [29] . Whether or not these channels contribute to the excitation-contraction coupling should depend on the amount of Ca 2+ displaced from the SR by oxytocin via IP 3 -sensitive fluorescent and luminescent proteins targeted to the SR and low-affinity Ca 2+ -sensitive dyes selectively loaded into the SR. A detailed discussion of these methods, their advantages and pitfalls has been published [30] . In our study, we combined the low-affinity Ca 2+ indicator Mag-Fluo-4 with a high-affinity dye Fura-2 to measure [Ca 2+ ] L and [Ca 2+ ] i simultaneously in freshly isolated uterine myocytes [31] . The data obtained in our experiments on rat myometrial cells suggest a very steep dependence between the SR filling state and the effectiveness of the IP 3 -mediated Ca 2+ release in intact cells [32] . ] i transients [32] . ] L . However, the possibility of the TrpC involvement in the oxytocin-induced [Ca 2+ ] i signaling still exists. In a recent study, a direct activation of extracellular Ca 2+ entry through TrpC by 1-oleoyl2acetyl-sn-glycerol, a membrane-permeant analog of DAG, was found in both primary uterine myocytes and immortalized myometrial cell line derived from pregnant uterus [18] . It has to be borne in mind that, under physiological conditions, the excitation-contraction cycle occurs spontaneously and the SR Ca 2+ release and entry induced by continuous oxytocin application will be imposed on the action potential triggered [Ca 2+ ] i transients. Therefore, the phasic effect of the elevated IP 3 level has to be viewed through the prism of the excitation-contraction coupling process. A generally accepted mechanism of the myometrial excitation-contraction coupling is that the action potential-induced rise in [Ca 2+ ] i triggers acto-myosin interaction by Ca
2+
-calmodulinmediated phosphorylation of the regulatory myosin light chains [33] . In the presence of oxytocin, or indeed any IP 3 producing agent, the amplitude of the action potential-induced [Ca 2+ ] i transients can, in principle, be potentiated by sustained elevation of IP 3 . The possibility of such potentiation stems from the bell-shaped Ca 2+ dependence of the IP 3 receptor sensitivity to IP 3 [34] . That is, at sub-maximal levels of IP 3 , the rise in [Ca ] i exceeds 500-600 nmol/L. The mechanism of oxytocin-induced changes in the frequency of contractions has not been elucidated yet. As the frequency effect of oxytocin is abolished by thapsigargin, it must be related to the IP 3 -mediated Ca 2+ release from the SR and concomitant activation of Ca 2+ activated channels [35, 36] . Clearly, the mechanism(s) of oxytocin-induced increase in frequency of uterine contractions can only be addressed once we understand the mechanism(s) of myometrial autorhythmicity.
Oxytocin-mediated Ca
2+ sensitization
Almost half a century of experimental research on many types of smooth muscle provided convincing evidence that contractility of smooth muscle is regulated not only by electromechanical coupling but also by membrane potentialindependent, pharmacomechanical coupling [37] . Many agonists induce sensitization of contractile apparatus to Ca 2+ by inhibiting myosin phosphatase and decreasing the rate of myosin regulatory chain dephosphorylation. This prolongs myosin light chain phosphorylation, leading to enhanced tension without influencing [Ca 2+ ] i [38, 39] . The contractile apparatus can therefore produce more force at given [Ca 2+ ] i . This also implies that the rate of relaxation will be decreased in the presence of agonist. Indeed, oxytocin decreases the rate of relaxation in human myometrium [40] . Figure 3A shows superimposed traces of force (upper traces) and its first derivative (lower traces) in control (blue traces) and in the presence of oxytocin (red traces). It is clear that oxytocin not only increases the amplitude and duration of contraction but also decreases the peak rate of relaxation. Similar results were obtained after thapsigargin treatment ( Figure 3B ) indicating SR Ca 2+ release is not involved in this process. Simultaneous measurements of [Ca 2+ ] i and force from human myometrium revealed that oxytocin applied to strips depolarized by KCl could increase force without affecting [Ca 2+ ] i [41] . In our experiments, oxytocin increased force without affecting peak amplitude of [Ca 2+ ] i transients [40] . Molecular mechanisms involved in Ca 2+ sensitization are currently being investigated in several laboratories. In many tissue types, RhoA, a monomeric G-protein, can mediate Ca 2+ sensitisation [42] . Activation occurs on stimulation of receptors coupled to Gα 12,13 ; Gα q or Gα i [43] , which convert inactive RhoA·GDP to active RhoA·GTP through the action of guanine nucleotide exchange factors. RhoA·GTP acts through a serine/threonine kinase (Rho kinase) that phosphorylates the regulatory subunit of MLCP, thereby inhibiting phosphatase activity. It has been shown that upregulation of RhoA and Rho kinase occurs in human myometrium during pregnancy [44] . It has also been demonstrated that inhibition of Rho kinase activity by Y-27632 reduces tension but not [Ca 2+ ] i during spontaneous and oxytocin-induced contractions in human myometrium [41] . Thus, Rho kinase mediates (at least in part) oxytocin-induced increase in myometrial contractility. This mechanism is summarized in Figure 4 . It remains to be determined whether Rho A is the activator of Rho kinase in myometrium. The oxytocin receptor has not been shown to couple to Gα 12,13 although activation of Rho A could occur through Gα q . The situation becomes even more complicated because arachidonic acid can also activate Rho kinase ( Figure 4 ) and might mediate Rho kinasedependent Ca 2+ sensitization [45] . In addition to Rho kinase, protein kinase C modulates myosin light chain phosphatase activity either by direct phosphorylation or a smooth-muscle specific inhibitor called CPI-17. Activation (phosphorylation) of CPI-17 inhibits the catalytic subunit of MLCP leading to increased light chain phosphorylation and enhanced contraction at a given [Ca 2+ ] i [46] . As Rho kinase [47] and arachidonic acid [45] also activate CPI-17, this suggests that these pathways could converge on CPI-17 to increase the [Ca 2+ ] i sensitivity of contractile apparatus.
It appears that Ca 2+ sensitization is the longest lasting effect of oxytocin on human myometrium. In fact, contractions of potentiated amplitude can be recorded for many hours, whereas increase in the base tone (incomplete relaxation) takes place only at the beginning of oxytocin application and lasts only a short time. Clearly, tonic contraction of the uterus during labor is undesirable as it would lead to foetal distress through decreased blood supply to the foetus. An increase in the amplitude and frequency of phasic contractions will aid successful labor. The data discussed in this review suggest that the tonic contraction seen at the beginning of oxytocin application (see Figure 1 ) and changes in frequency of contractions are mediated by the SR Ca 2+ , and potentiation of contraction amplitude is achieved by sensitization of contractile machinery to Ca . This process appears to be the most relevant physiologically and should be concentrated on in the future research. 
